ライフサイエンスコーパス: glycogen synthase kinase

1 Here we show that glycogen synthase kinase 3 (GSK-3) interacts with and ph

2 a-catenin pathway through phosphorylation of glycogen synthase kinase 3 (GSK-3), suggesting that this

3 racellular signal-regulated kinase (ERK) and glycogen synthase kinase 3 (GSK-3).

4 Glycogen synthase kinase 3 (GSK-3, isoforms alpha and be

5 but REDD1-mediated Nrf2 degradation required glycogen synthase kinase 3 (GSK3) activity and Ser-351/S

6 Glycogen synthase kinase 3 (GSK3) alpha and beta are 2 h

7 maller receptor-mediated vesicles containing glycogen synthase kinase 3 (GSK3) and protein arginine e

8 We show that glycogen synthase kinase 3 (GSK3) and protein arginine m

9 ion in p-AKT (S473), which in turn activated glycogen synthase kinase 3 (GSK3) and reduced beta-caten

10 cells due to its constant phosphorylation by glycogen synthase kinase 3 (GSK3) and subsequent proteas

11 Here we show how inhibiting glycogen synthase kinase 3 (GSK3) can improve the differ

12 ition of protein kinase C-beta (PKCbeta) and glycogen synthase kinase 3 (GSK3) causes synergistic apo

13 ng approaches, we show how the activation of glycogen synthase kinase 3 (GSK3) contributes to neurona

14 rt the evolutionary importance of the enzyme Glycogen Synthase Kinase 3 (GSK3) for maintaining podocy

15 differentiation through negatively affecting glycogen synthase kinase 3 (GSK3) function.

16 Herein, we investigated the role of glycogen synthase kinase 3 (GSK3) in liver regeneration

17 in collagen I 3D cultures in the absence of glycogen synthase kinase 3 (GSK3) inhibition, hPSC-deriv

18 Appropriate temporal application of a glycogen synthase kinase 3 (GSK3) inhibitor combined wit

19 Glycogen synthase kinase 3 (GSK3) inhibitors were identi

20 Here we report that glycogen synthase kinase 3 (GSK3) inhibits AMPK function

21 Glycogen synthase kinase 3 (GSK3) is a genetically valid

22 Here we show that glycogen synthase kinase 3 (Gsk3) is a metabolic sensor

23 Phosphorylation of glycogen synthase kinase 3 (GSK3) isoforms alpha/beta by

24 phosphodegron (CPD) signal, a target site of glycogen synthase kinase 3 (GSK3) kinase and Fbw7 ubiqui

25 Previous studies have indicated that glycogen synthase kinase 3 (GSK3) may play a role in APP

26 We also demonstrate that the kinase glycogen synthase kinase 3 (GSK3) mediates the FBW7-depe

27 Here, we show the expression of the Glycogen synthase kinase 3 (GSK3) MoGSK1 in M. oryzae is

28 we demonstrate a potent effect of inhibiting glycogen synthase kinase 3 (GSK3) on definitive endoderm

29 Suppression of glycogen synthase kinase 3 (GSK3) or FBXW7 rescued Mcl-1

30 PX-866 treatment abolished AKT/glycogen synthase kinase 3 (GSK3) phosphorylation, and c

31 Glycogen synthase kinase 3 (GSK3) plays a central role i

32 We also found that glycogen synthase kinase 3 (GSK3) regulated amyloid-beta

33 itor pools and plays a key role in mediating glycogen synthase kinase 3 (GSK3) signaling during brain

34 Here, we report that Wnt/glycogen synthase kinase 3 (GSK3) signaling functions po

35 ptor (D2R) and protein kinase B (PKB or Akt)/glycogen synthase kinase 3 (GSK3) signaling in the ventr

36 sites and secondary casein kinase 1 (CK1) or glycogen synthase kinase 3 (GSK3) sites was carefully ev

37 here show a novel mode of eIF6 regulation by glycogen synthase kinase 3 (GSK3) that is predominantly

38 Glycogen synthase kinase 3 (GSK3) was identified as an e

39 Glycogen synthase kinase 3 (GSK3), a prominent enzyme in

40 clock proteins by casein kinase 1 (CK1) and glycogen synthase kinase 3 (GSK3), appear conserved amon

41 Moreover, we show that glycogen synthase kinase 3 (GSK3), rather than mammalian

42 ation of proteins (Wnt/STOP), which inhibits glycogen synthase kinase 3 (GSK3)-dependent protein ubiq

43 Arabidopsis GLYCOGEN SYNTHASE KINASE 3 (GSK3)-like kinases play vari

44 mitochondrial respiratory quiescence through glycogen synthase kinase 3 (GSK3).

45 stabilizing many proteins phosphorylated by glycogen synthase kinase 3 (GSK3).

46 diated degradation due to phosphorylation by glycogen synthase kinase 3 (Gsk3).

47 gers a rapid lack of VDAC phosphorylation by glycogen synthase kinase 3 (GSK3).

48 al domain, priming it for phosphorylation by glycogen synthase kinase 3 (GSK3).

49 mine analogues which are inhibitors of human glycogen synthase kinase 3 (GSK3).

50 We show that this process is dependent on glycogen synthase kinase 3 (GSK3): GSK3 was associated w

51 pathways including phosphoinositide 3-kinase/glycogen synthase kinase 3 (PI3K/GSK3) signaling, with s

52 : it increases Akt phosphorylation, inhibits glycogen synthase kinase 3 activity, reduces IkappaB pho

53 hatidylinositol-dependent kinase 1 regulates glycogen synthase kinase 3 activity: a novel mechanism o

54 Acute responses of ERK1/2, p38, Akt, and glycogen synthase kinase 3 after mechanical stress were

55 atenin was required for BRB restoration, but glycogen synthase kinase 3 alpha/beta (GSK-3alpha/beta)

56 We demonstrate that inhibitors of glycogen synthase kinase 3 alpha/beta (GSK3alpha/beta) e

57 ing protein, p53, which is phosphorylated by glycogen synthase kinase 3 at serine 33 and then ubiquit

58 evealed increased phosphorylation of AKT and glycogen synthase kinase 3 beta (GSK-3beta) in both the

59 Glycogen synthase kinase 3 beta (GSK-3beta) is a central

60 through a kinome-wide screen, we found that glycogen synthase kinase 3 beta (GSK-3beta) was robustly

61 he virulence of P. gingivalis (Pg) affecting glycogen synthase kinase 3 beta (GSK-3beta)/nuclear fact

62 The BCR attenuates glycogen synthase kinase 3 beta (GSK3beta) activity to s

63 Glycogen synthase kinase 3 beta (GSK3beta) is a critical

64 Glycogen synthase kinase 3 beta (GSK3beta) is highly ina

65 We identify an interaction of BMP and Wnt/glycogen synthase kinase 3 beta (GSK3beta) pathways via

66 activator of smoothened, and phosphorylated glycogen synthase kinase 3 beta (pGSK-3B), an inactive f

67 we found that CAMK4 phosphorylates GSK3beta (glycogen synthase kinase 3 beta), activates the Wnt path

68 ibition of the pro-apoptotic molecules, JNK, glycogen synthase kinase 3 beta, or caspases, toxicity i

69 evealed a role for heat shock protein 90 and glycogen synthase kinase 3 but not casein kinase 1 nor L

70 nt which was suppressed by co-treatment with glycogen synthase kinase 3 inhibitor SB216763.

71 Our data reveal that glycogen synthase kinase 3 signaling also regulates eEF2

72 way seems to occur from Dishevelleds to axin/glycogen synthase kinase 3(GSK3)/beta-catenin complexes

73 d THC-induced downregulation of local GSK-3 (glycogen synthase kinase 3) and Akt signaling pathways d

74 cked cortical downregulation of local GSK-3 (glycogen synthase kinase 3) and Akt signaling pathways,

75 an be phosphorylated and stabilized by GSK3 (GLYCOGEN SYNTHASE KINASE 3)-like kinase BIN2 (BRASSINOST

76 (+) NPCs with a pharmacological inhibitor of glycogen synthase kinase 3, a known regulator of WNT sig

77 in sensitivity likely through increased Akt, glycogen synthase kinase 3, and AMPK phosphorylation; an

78 an inhibitor of cyclin-dependent kinases and glycogen synthase kinase 3, as a modulator of parkin rec

79 inhibition of Janus kinase 1, inhibition of Glycogen synthase kinase 3, or addition of NRG1 signific

80 screen for anti-fibrotic compounds targeting glycogen synthase kinase 3, which has a consistent role

81 y treating SH-SY5Y cells with inhibitors for glycogen synthase kinase 3-beta (GSK3beta) and cyclin-de

82 Insulin/GSK-3beta (glycogen synthase kinase 3-beta) signalling induces cycl

83 TA accelerated beta-catenin degradation by a glycogen synthase kinase 3-beta-dependent mechanism.

84 ytosis enzyme dynamin I via an inhibition of glycogen synthase kinase 3.

85 s of the brassinosteroid (BR) signaling, the glycogen synthase kinase 3/Arabidopsis SHAGGY-like kinas

86 The glycogen synthase kinase-3 (GSK-3) family of serine/thre

87 The role of glycogen synthase kinase-3 (GSK-3) in Alzheimer disease

88 The challenge for glycogen synthase kinase-3 (GSK-3) inhibitor design lies

89 plex 1 (mTORC1) inhibitor rapamycin, and the glycogen synthase kinase-3 (GSK-3) inhibitor lithium act

90 Combining glycogen synthase kinase-3 (GSK-3) inhibitors with VPA o

91 Activation of glycogen synthase kinase-3 (GSK-3) interferes with micro

92 Glycogen synthase kinase-3 (GSK-3) is a constitutively a

93 Glycogen synthase kinase-3 (Gsk-3) is a key regulator of

94 Glycogen synthase kinase-3 (GSK-3) is a key regulator of

95 Glycogen synthase kinase-3 (GSK-3) is one of the few sig

96 bition of the histone deacetylase (HDAC) and glycogen synthase kinase-3 (GSK-3) pathways, which cause

97 Glycogen synthase kinase-3 (GSK-3) regulates multiple ce

98 de et al. uses phosphoproteomics to identify glycogen synthase kinase-3 (GSK-3) substrates in mouse e

99 DydA is phosphorylated by glycogen synthase kinase-3 (GSK-3), which is required fo

100 together with inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3), which relieves its i

101 Predictably, inhibition of glycogen synthase kinase-3 (GSK-3), which results from a

102 nt oxazole-4-carboxamide-based inhibitors of glycogen synthase kinase-3 (GSK-3).

103 ling events that result in the inhibition of glycogen synthase kinase-3 (GSK-3)beta represent an adap

104 ositol-3 kinase/Akt (IRS-PI3K-Akt) pathways, glycogen synthase kinase-3 (GSK3) and mammalian target o

105 T3 signaling, and simultaneous inhibition of glycogen synthase kinase-3 (GSK3) and MAP kinase/ERK kin

106 Glycogen synthase kinase-3 (GSK3) are ubiquitously expre

107 haracterize a novel activation mechanism for glycogen synthase kinase-3 (GSK3) by the sphingolipids p

108 The glycogen synthase kinase-3 (GSK3) family kinases are cen

109 Treatment with lithium or a glycogen synthase kinase-3 (GSK3) inhibitor corrects beh

110 ia containing fetal bovine serum (FBS) and a glycogen synthase kinase-3 (GSK3) inhibitor, and in seru

111 e describe a cell-engineering strategy using glycogen synthase kinase-3 (GSK3) inhibitor-loaded nanop

112 Here, we report that glycogen synthase kinase-3 (GSK3) is a critical determin

113 Glycogen synthase kinase-3 (GSK3) is an important signal

114 Hippocampal glycogen synthase kinase-3 (GSK3) is hyperactive in the

115 We found that glycogen synthase kinase-3 (GSK3) is overactivated in co

116 gated the effect of inhibitors targeting the glycogen synthase kinase-3 (GSK3) on the expression of N

117 Moreover, induction of glycogen synthase kinase-3 (GSK3) performed using a Wnt

118 Glycogen synthase kinase-3 (GSK3) regulates many physiol

119 Glycogen synthase kinase-3 (GSK3) was found to be an ups

120 rrent study, we tested whether inhibitors of glycogen synthase kinase-3 (GSK3), previously reported t

121 ogenesis, immunomodulation and regulation of glycogen synthase kinase-3 activity.

122 lian target of rapamycin signaling, glucose, glycogen synthase kinase-3 and liver kinase B1, protein

123 ardiomyocytes in early developmental stages, glycogen synthase kinase-3 and p38 mitogen-activated pro

124 Next, we apply this strategy to study glycogen synthase kinase-3 beta (GSK-3beta), a kinase ab

125 Glycogen synthase kinase-3 beta (GSK-3beta), a serine/th

126 drogenase kinase-1, or its downstream target glycogen synthase kinase-3 did not prevent CCR9 expressi

127 Glycogen synthase kinase-3 is a Ser/Thr kinase, tonicall

128 enhanced risk for SZ and/or BD can activate glycogen synthase kinase-3 isozymes (GSK3alpha and beta)

129 The glycogen synthase kinase-3 of the parasite (PfGSK-3) was

130 Pharmacological inhibition of glycogen synthase kinase-3 was sufficient to reverse the

131 , while application of Bikinin (inhibitor of glycogen synthase kinase-3), which activated BR signalin

132 to ERK1/2 and Akt, including p70 S6-kinase, glycogen synthase kinase-3, ribosomal S6 kinase, c-Jun,

133 hium chloride, a reversible inhibitor of the glycogen synthase kinase-3, that rescued NMJ defects in

134 lation primes for Ser-159 phosphorylation by glycogen synthase kinase-3.

135 y phosphorylated at Thr(714) and Ser(727) by glycogen synthase kinase 3alpha and -beta (GSK-3alpha/be

136 m of this study was to determine the role of glycogen synthase kinase-3alpha (GSK-3alpha) in post-MI

137 eta-catenin signaling cascades, which switch glycogen synthase kinase 3beta (GSK-3beta) activation on

138 Phosphorylation of tau at Thr212 and glycogen synthase kinase 3beta (GSK-3beta) at Ser9 was r

139 ave been some reports on MTDLs targeting the glycogen synthase kinase 3beta (GSK-3beta) enzyme, due t

140 Glycogen synthase kinase 3beta (GSK-3beta) has been sugg

141 Glycogen synthase kinase 3beta (GSK-3beta) is a primary

142 Glycogen synthase kinase 3beta (GSK-3beta) is an enzyme

143 ected T cells and reduces phosphorylation of glycogen synthase kinase 3beta (GSK-3beta), a downstream

144 of cyclin B1, cyclin D3, and phosphorylated glycogen synthase kinase 3beta (GSK-3beta), while infect

145 ion of specific Akt substrates, most notably glycogen synthase kinase 3beta (Gsk-3beta).

146 ound a residue that can be phosphorylated by glycogen synthase kinase 3beta (GSK-3beta).

147 Consequently, GRbeta-Ad mice had increased glycogen synthase kinase 3beta (GSK3beta) activity and r

148 , N-methyl-d-aspartate receptor function, or glycogen synthase kinase 3beta (GSK3beta) activity or ex

149 ver, hypoinsulinemia leads to an increase in glycogen synthase kinase 3beta (GSK3beta) activity that,

150 ssociated with insulin resistance, decreased glycogen synthase kinase 3beta (GSK3beta) activity, acti

151 (NF-kappaB) pathway and in the induction of glycogen synthase kinase 3beta (GSK3beta) activity, resu

152 of beta-catenin by enhancing binding between glycogen synthase kinase 3beta (GSK3beta) and beta-caten

153 osphorylation on p53 at Ser-33 and Ser-37 by glycogen synthase kinase 3beta (GSK3beta) and DNA-depend

154 Cellular targets of Li(+), such as glycogen synthase kinase 3beta (GSK3beta) and G proteins

155 oteasomal degradation via phosphorylation by glycogen synthase kinase 3beta (GSK3beta) and recognitio

156 ted protein kinase kinase 4 (MKK4), JNK, and glycogen synthase kinase 3beta (GSK3beta) and thereby de

157 (APC), casein kinase 1alpha (CK1alpha), and glycogen synthase kinase 3beta (GSK3beta) and undergoes

158 TGF-beta1 expression and hyperacetylation of glycogen synthase kinase 3beta (GSK3beta) at residue K15

159 tes diminished inhibitory phosphorylation of glycogen synthase kinase 3beta (GSK3beta) at Ser-9 in th

160 ects against hepatic steatosis by inhibiting glycogen synthase kinase 3beta (GSK3beta) by enhancing s

161 Glycogen synthase kinase 3beta (GSK3beta) deactivation a

162 Glycogen synthase kinase 3beta (GSK3beta) has been shown

163 ppress many signaling pathways that activate glycogen synthase kinase 3beta (GSK3beta) implicated in

164 quent signaling, causing overt activation of glycogen synthase kinase 3beta (GSK3beta) in nerves of m

165 synthesis is associated with inactivation of glycogen synthase kinase 3beta (GSK3beta) in renal cells

166 A member of this family is glycogen synthase kinase 3beta (GSK3beta) interaction pr

167 We show that glycogen synthase kinase 3beta (GSK3beta) interacts with

168 Glycogen synthase kinase 3beta (GSK3beta) is a constitut

169 Inhibition of glycogen synthase kinase 3beta (GSK3beta) is a shared ac

170 g pathway involving AKT Ser/Thr kinase (AKT)/glycogen synthase kinase 3beta (GSK3beta) or paxillin.

171 of TGF-beta receptors and p38 MAPK increased glycogen synthase kinase 3beta (GSK3beta) phosphorylatio

172 In this study, we demonstrate that glycogen synthase kinase 3beta (GSK3beta) regulates ST2L

173 d by the core clock oscillator BMAL1 and AKT/glycogen synthase kinase 3beta (GSK3beta) signaling path

174 ide 3-kinase (PI3K)-AKT Ser/Thr kinase (AKT)-glycogen synthase kinase 3beta (GSK3beta) signaling path

175 [e.g., strong bias toward phosphorylation of glycogen synthase kinase 3beta (GSK3beta) via the full-l

176 peractivation and subsequent inactivation of glycogen synthase kinase 3beta (GSK3beta), a negative re

177 e IGF-I, IGF binding protein-1 (IGFBP-1) and glycogen synthase kinase 3beta (GSK3beta), as one major

178 Psychotropic medications target glycogen synthase kinase 3beta (GSK3beta), but the funct

179 ivation, which results in hyperactivation of glycogen synthase kinase 3beta (GSK3beta), followed by p

180 The phosphorylation is catalyzed by glycogen synthase kinase 3beta (GSK3beta), ultimately re

181 hic signaling intermediates, such as Akt and glycogen synthase kinase 3beta (GSK3beta), were dephosph

182 y sites in the N-terminus of beta-catenin as glycogen synthase kinase 3beta (GSK3beta), which are rec

183 CUGBP1 activity is controlled by glycogen synthase kinase 3beta (GSK3beta), which is elev

184 dent on LFA-1/ICAM-1-induced inactivation of glycogen synthase kinase 3beta (GSK3beta), which is medi

185 the canonical regulation of beta-catenin via glycogen synthase kinase 3beta (GSK3beta)-dependent degr

186 PI exposure abrogated glycogen synthase kinase 3beta (GSK3beta)-mediated degra

187 1 interacts with Nrf2 and stabilizes it from glycogen synthase kinase 3beta (GSK3beta)-mediated phosp

188 FN signaling pathways occurs at the point of glycogen synthase kinase 3beta (GSK3beta)-TANK-binding k

189 t VRK2 activity was negatively controlled by glycogen synthase kinase 3beta (GSK3beta).

190 g protein binding protein kinase A (PKA) and glycogen synthase kinase 3beta (GSK3beta).

191 These include protein kinase A (PKA) and glycogen synthase kinase 3beta (GSK3beta).

192 ivation and this occurs in part by targeting glycogen synthase kinase 3beta (GSK3beta).

193 inhibition of the tumor suppressors PTEN and glycogen synthase kinase 3beta (GSK3beta).

194 at S199 (hTau-S199-P) by the protein kinase glycogen synthase kinase 3beta (GSK3beta).

195 n (mTOR) signaling pathway and inhibition of glycogen synthase kinase 3beta (GSK3beta).

196 atty acids, and this suppression depended on glycogen synthase kinase 3beta activation and induction

197 au phosphorylation and solubility, increased glycogen synthase kinase 3beta activity, compromised lon

198 protein that plays a key role in attenuating glycogen synthase kinase 3beta activity, leading to aber

199 2A and recruits protein phosphatase 2A with glycogen synthase kinase 3beta and beta-catenin, inducin

200 Glycogen synthase kinase 3beta and Foxo1 are two PI-3K-r

201 isms involved demonstrate that ASPH binds to glycogen synthase kinase 3beta and inhibits its subseque

202 ibition of ASPH activity, phosphorylation of glycogen synthase kinase 3beta and p16 expression were i

203 reasing Ser9 phosphorylation-inactivation of glycogen synthase kinase 3beta by RBMY, thereby impeding

204 ted with release of the inhibitory effect of glycogen synthase kinase 3beta function by decreasing Se

205 in, and that beta-catenin activation through glycogen synthase kinase 3beta inhibition leads to FANCC

206 decreased DJ-1 and increased phosphorylated glycogen synthase kinase 3beta levels may account for im

207 Wnt/beta-catenin pathway by inactivation of glycogen synthase kinase 3beta of NKT cells.

208 ment, and reduced Akt (protein kinase B) and glycogen synthase kinase 3beta phosphorylation.

209 al nuclear factor kappaB pathway and the Akt-glycogen synthase kinase 3beta signaling axis, respectiv

210 bound IRF1 turnover is promoted by GSK3beta (Glycogen Synthase Kinase 3beta) via phosphorylation of t

211 increase in phospho-beta-catenin and active glycogen synthase kinase 3beta, a kinase known to target

212 t3a (the canonical activator), inhibitors of glycogen synthase kinase 3beta, and small-interfering RN

213 cocorticoid kinase 1 (SGK1), an inhibitor of glycogen synthase kinase 3beta, as part of this pathway.

214 ver, inhibition of protein phosphatase 1 and glycogen synthase kinase 3beta, downstream targets of Ca

215 ced tumor growth, induced phosphorylation of glycogen synthase kinase 3beta, enhanced p16 expression

216 n showed AQP1 interaction with beta-catenin, glycogen synthase kinase 3beta, LRP6, and Axin1.

217 of cyclin-dependent protein kinase 5 (Cdk5), glycogen synthase kinase 3beta, protein phosphatase 1, o

218 e kinase 3beta by RBMY, thereby impeding the glycogen synthase kinase 3beta-dependent degradation of

219 Molecularly, ROCK inhibition induced glycogen synthase kinase 3beta-dependent phosphorylation

220 ta-catenin expression and stabilization in a glycogen synthase kinase 3beta-independent manner.

221 signal-regulated protein kinase modules and glycogen synthase kinase 3beta.

222 ) transcriptional activity via inhibition of glycogen synthase kinase 3beta.

223 ead box protein O1 transcription factors and glycogen synthase kinase 3beta.

224 7, p38 mitogen-activated protein kinase, and glycogen synthase kinase 3beta.

225 nalling proteins, protein kinase B (Akt) and glycogen synthase-kinase 3beta, in maternal liver (P < 0

226 Recent evidence suggests that glycogen-synthase kinase 3beta (GSK3beta) plays a key ro

227 rexpression of TDP-43 leads to activation of glycogen synthase kinase-3beta (GSK-3beta) and that GSK-

228 dated AD targets beta-secretase (BACE-1) and glycogen synthase kinase-3beta (GSK-3beta) by attacking

229 PSC-CMs in vitro (i.e., 100- to 250-fold) by glycogen synthase kinase-3beta (GSK-3beta) inhibition us

230 In addition, application of glycogen synthase kinase-3beta (GSK-3beta) inhibitor com

231 etin, reactivation of beta-catenin using the glycogen synthase kinase-3beta (GSK-3beta) inhibitor LiC

232 Herein we report that glycogen synthase kinase-3beta (GSK-3beta) is phosphoryl

233 sis coli tumor suppressor protein (APC), and glycogen synthase kinase-3beta (GSK-3beta), which could

234 atocytes, which led to a delayed increase in glycogen synthase kinase-3beta (GSK-3beta)-mediated hepa

235 demonstrate that alcohol intake also blocks glycogen synthase kinase-3beta (GSK-3beta)-phosphorylati

236 ein function are via a pathway that involves glycogen synthase kinase-3beta (GSK-3beta).

237 teins, which were predicted to be targets of glycogen synthase kinase-3beta (GSK-3beta).

238 hase and the phosphorylation (inhibition) of glycogen synthase kinase-3beta (GSK-3beta).

239 Glycogen synthase kinase-3beta (GSK3beta) activity is in

240 nted pre-synaptic protein deficit, decreased glycogen synthase kinase-3beta (GSK3beta) activity, and

241 finding is the pronounced downregulation of glycogen synthase kinase-3beta (Gsk3beta) and upregulati

242 Glycogen synthase kinase-3beta (GSK3beta) controls many

243 Glycogen synthase kinase-3beta (GSK3beta) has diverse bi

244 Here we demonstrate that hyperactivity of glycogen synthase kinase-3beta (GSK3beta) in the atrium

245 Glycogen synthase kinase-3beta (GSK3beta) plays a critic

246 uclear Nrf2 export/degradation machinery via glycogen synthase kinase-3beta (Gsk3beta) signaling was

247 lted in increased phosphorylation of Akt and glycogen synthase kinase-3beta (GSK3beta), leading to en

248 tion and insulin secretion via regulation of glycogen synthase kinase-3beta (GSK3beta).

249 ith emerin and beta-actin, and activation of glycogen synthase kinase-3beta (GSK3beta).

250 s (ankyrin G, EB1) were knocked down or when glycogen synthase kinase-3beta (GSK3beta; an AD-associat

251 panied by hyperphosphorylation of substrates glycogen synthase kinase-3beta and mammalian target of r

252 hase survival pathway, and the inhibition of glycogen synthase kinase-3beta and nuclear factor kappa

253 ion and completely blocked the inhibition of glycogen synthase kinase-3beta gene transcription.

254 Overexpression of Snail1 and inhibition of glycogen synthase kinase-3beta in colorectal tumor cells

255 Such glycogen synthase kinase-3beta inactivation causes chang

256 erentiated hPSCs into mesoderm cells using a glycogen synthase kinase-3beta inhibitor for 3 days, the

257 mbinant Wnt3a protein or CHIR-99021 (CHIR, a glycogen synthase kinase-3beta inhibitor) caused a dose-

258 ha/wrd pathway in the motoneuron antagonizes glycogen synthase kinase-3beta kinase activity to preven

259 on of GABAergic transmission via D2 receptor-glycogen synthase kinase-3beta signaling dramatically re

260 The phosphorylation and inactivation of glycogen synthase kinase-3beta was dependent on mammalia

261 GSK-3beta (glycogen synthase kinase-3beta) is highly associated wit

262 l as by inhibition of the Akt-GSK-3beta (Akt-glycogen synthase kinase-3beta) pathway.

263 orylation of the inhibitory Ser-9 residue of glycogen synthase kinase-3beta, a primary Tau kinase inv

264 ollowed by phosphorylation (inactivation) of glycogen synthase kinase-3beta, at least in part via STA

265 cyclin D1, E-cadherin, beta-catenin, Dvl-1, glycogen synthase kinase-3beta, axin-1, and adenomatous

266 no changes in Ctnnb1 expression, activity of glycogen synthase kinase-3beta, known to phosphorylate a

267 activator of beta-catenin via inhibition of glycogen synthase kinase-3beta, reversed the inhibition

268 on, and increased phosphorylation of Akt and glycogen synthase kinase-3beta, ultimately resulting in

269 d to the phosphorylation and inactivation of glycogen synthase kinase-3beta, which resulted in inhibi

270 inding (CREB) protein levels to decreaseviaa glycogen synthase kinase-3beta-dependent mechanism.

271 pstream signaling pathways known to regulate glycogen synthase kinase-3beta.

272 ial-mesenchymal transition by repressing AKT/glycogen synthase kinase-3beta/beta-catenin signaling.

273 ological or genetic inhibition of tau kinase glycogen-synthase-kinase-3beta (GSK-3beta).

274 Additionally, in the current study, glycogen synthase kinase appears to attenuate tau pathol

275 In both cell types, insulin blocks glycogen synthase kinase beta (GSK3beta) activity.

276 Apc participates in a complex that includes glycogen synthase kinase beta (Gsk3beta) and betacatenin

277 Here we show that the glycogen synthase kinase beta (GSK3beta) expression is e

278 In a previous study, the FGK3 glycogen synthase kinase gene orthologous to mammalian G

279 PKB/Akt in turn inactivates glycogen synthase kinase (GSK) 3, a major regulator of m

280 Studies have implicated signaling through glycogen synthase kinase (GSK) 3alpha/beta in the activa

281 work, we demonstrate that overexpression of glycogen synthase kinase (GSK) 3beta in neural precursor

282 Glycogen synthase kinase (GSK)-3 is a ubiquitously expre

283 CRMP-2 and ROCK II is partially regulated by glycogen synthase kinase (GSK)-3 phosphorylation of CRMP

284 The enzymes 5-lipoxygenase (5-LO) and glycogen synthase kinase (GSK)-3 represent promising dru

285 Blast TBI increased glycogen synthase kinase (GSK)-3beta activities in ApoE4

286 These same stimuli enhance glycogen synthase kinase (GSK)-3beta activity through in

287 n vitro and in vivo, working through the Akt/Glycogen Synthase Kinase (GSK)-3beta pathway.

288 Glycogen synthase kinase (GSK)-3beta phosphorylates the

289 eptor is modulated, here, we have found that glycogen synthase kinase (GSK)-3beta phosphorylation of

290 Here, we provide evidence that glycogen synthase kinase (GSK)-3beta promotes cell proli

291 rved that phosphorylation of Gpa2 depends on glycogen synthase kinase (GSK).

292 show that the dual phosphodiesterase (PDE)7- glycogen synthase kinase (GSK)3 inhibitor, VP3.15, a het

293 Mechanistically, Tanshinone IIA blunted glycogen synthase kinase (GSK)3beta overactivity and hyp

294 used to deliver low doses of small molecule glycogen synthase kinase (GSK-3) antagonists that promot

295 sly showed that the serine/threonine kinase, glycogen synthase kinase, GSK-3alpha/beta, is a central

296 exerted its positive effect by inhibition of glycogen synthase kinase (GSK3) activity and enhancement

297 contrast, phosphomimetic substitution of the glycogen synthase kinase (GSK3beta) site in the Pro/Ala-

298 A point mutation in a putative glycogen synthase kinase phosophorylation site within th

299 lates alcohol-induced BK internalization via glycogen synthase kinase phosphorylation.

300 f lithium, in which fine-tuned regulation of glycogen synthase kinase type 3, a prime target for lith